LOUISVILLE, Ky. -- A CD70-targeted CAR T-cell therapy for advanced kidney cancer continued to show durable activity in ...

Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, today announced that the U.S. Food and ...

Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, today announced that the U.S. Food and ...

I just look back and say, 'Thank God I made it through.' As a toddler in Cincinnati, Ohio, William was diagnosed with hemophagocytic lymphohistiocytosis, a rare, life-threatening disorder in which the ...

Outzen was recently diagnosed with HLH (Hemophagocytic lymphohistiocytosis), a severe, systemic inflammatory syndrome, ...

In the US, emapalumab-lzsg is indicated for pediatric (newborn and older) and adult primary hemophagocytic lymphohistiocytosis (HLH) patients with refractory, recurrent or progressive disease, or ...

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

IEC-HS includes the preferred terms IEC-HS, HLH, Hemophagocytic lymphohistiocytosis, and atypical HLH. Two patients developed an inflammatory syndrome prior to the existence of IEC-HS as a term in ...

In the setting of this urgency, drug repurposing emerged as a powerful strategy for identifying potential treatments -- utilizing medications already available on pharmacy shelves around the world.

ALLO-316, a CD70-targeting CAR T-cell therapy, has demonstrated activity in patients with previously treated, advanced ccRCC.

Hemophagocytic Lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS): In patients receiving ABECMA in the KarMMa and KarMMa-3 studies, HLH/MAS occurred in 2.9% (10/349) of patients.